enGene Therapeutics Inc. (ENGN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, enGene Therapeutics Inc. (NASDAQ: ENGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.53 (0.00% 1D, market cap $102.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENGN ranks #714 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ENGN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BDTX (Black Diamond Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M). Among the 5-stock peer group, ENGN leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per ENGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001980845), enGene Therapeutics Inc. generated $0 in revenue, -$117.3M in net income, and -$100.7M in free cash flow against $337.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ENGN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.61) forces dealer call-delta covering toward $12.86.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
enGene Therapeutics Inc. (ENGN) slipped 0.00% to $1.53, trading at 2% of its 52-week range ($1.4 – $12.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
2026-10-19. The following slide deck was published by enGene Therapeutics Inc.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, enGene Therapeutics Inc. (ENGN) ranks #714 by composite RQD confidence (34/100, grade E) and #659 by equity capitalization ($102.5M). Within this direct 5-issuer industry benchmark cohort, ENGN leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ENGN at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENGN
ACTIVE
enGene Therapeutics Inc. | E | 34/100 | — | — | -35.0% | 0.00% | $102.5M | Benchmark Subject |
| BDTX Black Diamond Therapeutics Inc. | C- | 59/100 | — | — | 10.8% | -4.30% | $106.9M | /bdtx-vs-engn → |
| VYGR Voyager Therapeutics Inc. | E | 15/100 | — | — | -35.0% | -2.27% | $108.4M | /vygr-vs-engn → |
| LENZ LENZ Therapeutics Inc. | D | 44/100 | — | 96.0% | -27.8% | -12.61% | $109.7M | /lenz-vs-engn → |
| TVGN Tevogen Inc. | D- | 40/100 | — | — | -35.0% | -2.48% | $95.2M | /tvgn-vs-engn → |
In its most recent audited fiscal period (FY2025, filed 2025-10-31), enGene Therapeutics Inc. (ENGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$117.3M, operating cash flow of -$99.2M, and free cash flow of -$100.7M (-104.7% YoY). On the balance sheet, ENGN closed FY2025 with $337.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-10-31 | $0 | -$117.3M | -$99.2M | -$100.7M | $337.1M | — |
| FY2024 (FY) | 2024-10-31 | $0 | -$55.1M | -$48.3M | -$49.2M | $285.9M | — |
| FY2023 (FY) | 2023-10-31 | $0 | -$99.9M | -$24.7M | -$24.7M | — | — |
As of 2026-11-02, enGene Therapeutics Inc. (NASDAQ: ENGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.53 (0.00% 1D, market cap $102.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENGN ranks #714 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ENGN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BDTX (Black Diamond Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M). Among the 5-stock peer group, ENGN leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).
Per ENGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001980845), enGene Therapeutics Inc. generated $0 in revenue, -$117.3M in net income, and -$100.7M in free cash flow against $337.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ENGN last traded at $1.53 (0.00% on volume of 1,197,769 shares), positioning the stock -14.53% below its 50-day simple moving average ($1.79) and -64.67% below its 200-day simple moving average ($4.33). Across its 52-week range of $1.40 to $12.25, ENGN sits at the 1.2% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($1.35 to $1.71).
Why ENGN Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).